Filing Flows › Sunshine Biopharma (SBFM) › Q2 2026
Sunshine Biopharma (SBFM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Sunshine Biopharma (SBFM) reported revenue of $9.3M for the second quarter 2026 (Q2 2026), -2% from a year earlier and +15% from the quarter before. Operating margin was -17.4%, net loss $1.6M (16.9% of revenue).
Sunshine Biopharma, Q2 2026: revenue $9.3M (-2% year over year), operating margin -17.4%, net loss $1.6M, operating cash flow −$918K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.3M | +15% | -2% |
| Operating profit | −$1.6M | — | — |
| Net earnings | −$1.6M | — | — |
| Operating cash flow | −$918K | — | — |
What changed
Revenue was $9.3M in Q2 2026, down 2% year over year and up 15% from the previous quarter.
Gross margin was 26.2%, down 10.2 points from Q2 2025. Operating costs exceeded revenue by $1.6M, an operating margin of -17.4%. Operating expenses fell 26% while revenue fell 2%. The quarter ended with a net loss of $1.6M, wider than the previous quarter's $1.2M loss.
Operating cash flow was −$918K. Non-cash charges added back $78K of depreciation and amortization. Working capital and other items added $568K. Capital expenditures of $7K exceeded it, leaving free cash flow of −$925K.
Questions
What was Sunshine Biopharma's revenue in the second quarter 2026?
Sunshine Biopharma (SBFM) reported revenue of $9.3M for the second quarter 2026 (Q2 2026), -2% from a year earlier and +15% from the quarter before.
Was Sunshine Biopharma profitable in the second quarter 2026?
Operating loss was $1.6M (-17.4% of revenue) and net loss $1.6M.
Source: Sunshine Biopharma 10-Q on SEC EDGAR.